Comorbidity, age and overall survival in patients with advanced pancreatic cancer - Results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placebo

Low baseline pain intensity and better PS were associated with improved overall survival, while age and comorbidity were not independent prognostic factors for patients treated with gemcitabine-based therapy.